<DOC>
	<DOCNO>NCT01817790</DOCNO>
	<brief_summary>This study design investigate efficacy fluticasone propionate ( FP ) ocular symptom associate allergic rhinitis ( AR ) .</brief_summary>
	<brief_title>Assessment Fluticasone Propionate Ocular Allergy Symptoms</brief_title>
	<detailed_description>While current FP approve indication GSK market formulation limit treatment nasal symptom , several large well-controlled study FP maintain adequate control nasal symptom administer dose 200 microgram ( mcg ) once-daily ( QD ) also suggest improvement ocular symptom . This study employ randomize , double-blind , parallel group , multi-center design compare FP placebo nasal spray subject seasonal allergic rhinitis ( SAR ) ass effectiveness ocular symptom associate AR .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>1 . Participants good general health ( opinion investigator ) clinically significant relevant abnormality medical history 2 . Participants diagnosis seasonal allergic rhinitis 1 . A clinical history ( write verbal confirmation ) allergic rhinitis seasonal onset offset nasal ocular allergy symptom last 2 mountain cedar pollen allergy season . 2 . A positive skin test reaction ( least ) relevant allergen , mountain cedar pollen , determine skin prick method perform within 12 month Visit 1 ) . 3 . Participants allergic rhinitis symptom least moderate severity randomization : 1 . An iTOSS ≥ 4 iNCSS ≥2 morning randomization ( Visit 3/Baseline ) . 2 . An averaged ( rTOSS ) ≥ 4 , average rNCSS ≥2 three five day placebo lead 4 . Participant reside within geographical environment exposure mountain cedar pollen significant entire study period . 5 . Participant demonstrate understand study willingness participate evidence voluntary write informed consent/assent receive sign date copy inform consent/assent form . Children , age 12 17 require sign assent form part inform consent process . 1 . Participants know suspected intolerance hypersensitivity study material ( closely relate compound ) state ingredient . 2 . Participants nasal disorder like : 1. injury surgery nose investigator believe would interfere participation study . 2. previously diagnose severe physical obstruction nose ( e.g. , deviated septum ) could affect deposition doubleblind intranasal study drug . 3 . Rhinitis medicamentosa 3 . Participants historical current evidence clinically significant uncontrolled disease like asthma , cardiac arrhythmia , hypertension , diabetes mellitus , ocular herpes , glaucoma , hepatic renal disease , malignancy etc . 4 . Presence symptom active bacterial viral infection . 5 . Participants conjunctivitis cause infectious agent . 6 . Participants current , single eye bilateral cataract participant cataract surgery within/less 3 month</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>